SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, will showcase for the first time its new global portfolio of real-time continuous glucose monitoring (CGM) systems at the 15th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) held April 27-30, 2022 in Barcelona. The expanded portfolio includes Dexcom ONE, Dexcom G6 and the upcoming Dexcom G7, a range of exceptionally accurate,* real-time CGM systems designed to empower more people living with diabetes than ever before.

“For two decades, Dexcom has tirelessly innovated to provide the most accurate, connected and accessible CGM technology to people with diabetes around the globe,” said Kevin Sayer, chairman, president and CEO of Dexcom. “Diabetes is not a one-size-fits-all condition—people deserve choice in how they manage their disease. We are excited to be able to provide three gold standard CGM systems that meet the differing needs of people with diabetes.”

Each system in the portfolio offers a different set of features and functionality for various needs across diabetes management; however, all three Dexcom systems eliminate burdensome scanning and painful fingerpricks† for calibration and diabetes treatment decisions.

The Dexcom Real-Time CGM Portfolio

Dexcom ONE rtCGM made more accessible

“Innovation, accuracy and reliability have always been at the core of our work to provide the diabetes community with the best technology possible,” said Chad Patterson, executive vice president of global marketing and product management at Dexcom. “It’s our priority to offer as many people access to the highest standard of care and this portfolio of real-time CGM systems delivers on that commitment.”

In addition to the introduction of Dexcom’s expanded product portfolio, key posters and research presented at ATTD continue to affirm the use of Dexcom CGM is central to optimal diabetes management. Some of these educational presentations may make claims exceeding those cleared by FDA for the labeling of these devices.

Dexcom CGM Accuracy, Performance and Feature Engagement:

Dexcom Connectivity and Closed Loop Systems:

Health Outcomes, Economic Outcomes and Market Access:

For more information about the 15th International Conference on Advanced Technologies and Treatments for Diabetes and to register to virtually attend the conference, visit https://attd.kenes.com/registration/.

DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.

*Dexcom G6, Dexcom G7, and Dexcom ONE User Guides. To obtain the Instructions for use for these products, click here. Note that labeling may differ in different countries.

†If your glucose alerts and readings from Dexcom ONE, Dexcom G6 or Dexcom G7 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

‡To view a list of compatible smart devices, visit dexcom.com/compatibility

‡‡Dexcom is working closely with its insulin pump partners to integrate Dexcom G7 into current and future automated insulin delivery systems as quickly as possible

1 510(k) pending. Not available for sale in the United States.

© 2022 Dexcom, Inc. Dexcom, Dexcom ONE, Dexcom G6, Dexcom G7 and Dexcom Clarity are registered trademarks of DexCom, Inc. in the U.S., and may be registered in other countries. All rights reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220425006053/en/

Media Contact James McIntosh 619-884-2118 james.mcintosh@dexcom.com

Investor Contact Sean Christensen 858-203-6657 sean.christensen@dexcom.com

View this news release online at: http://www.businesswire.com/news/home/20220425006053/en

© 1985 - 2022 BioSpace.com. All rights reserved. Powered by Madgex Job Board Software